Kymera Therapeutics has been granted a patent for a method to treat MYD88-mutant B-cell lymphomas using an IRAK4 degrader. The method involves administering Compound A or its salt to the patient at a dose of up to 1600 mg. GlobalData’s report on Kymera Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kymera Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kymera Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Kymera Therapeutics's grant share as of January 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of myd88-mutant b-cell lymphomas using irak4 degrader

Source: United States Patent and Trademark Office (USPTO). Credit: Kymera Therapeutics Inc

A recently granted patent (Publication Number: US11857535B2) discloses a method for treating MYD88-mutant B-cell lymphoma in patients by administering Compound A or its pharmaceutically acceptable salt. The compound is administered at varying doses ranging from 10 mg/m2 to 1600 mg, either orally or intravenously, once or twice weekly, in different administration cycles. The patent also covers the use of pharmaceutical compositions containing Compound A with excipients or carriers.

The method outlined in the patent is specifically targeted towards treating MYD88-mutant B-cell lymphoma, including various subtypes such as ABC DLBCL, primary CNS lymphomas, and Hodgkin's lymphoma, among others. Patients who have previously undergone therapy and are human are eligible for this treatment. The patent provides detailed instructions on the dosage, administration route, frequency, and composition of Compound A for effective treatment of MYD88-mutant B-cell lymphoma, emphasizing the importance of personalized treatment strategies in combating this type of cancer.

To know more about GlobalData’s detailed insights on Kymera Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies